^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDKN2A mutation + CDKN2B mutation + KRAS mutation

    i
    Other names: CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A, CDKN2B, Cyclin Dependent Kinase Inhibitor 2B, Cyclin-Dependent Kinase Inhibitor 2B (P15, Inhibits CDK4), Cyclin-Dependent Kinase 4 Inhibitor B, Multiple Tumor Suppressor, P14-INK4b, P15-INK4b, MTS-2, MTS2, Cyclin-Dependent Kinases 4 And 6 Binding Protein, CDK Inhibitory Protein, P14_CDK Inhibitor, P15 CDK Inhibitor, CDK4B Inhibitor, P14_INK4B, P15_INK4B, P15INK4b, P15INK4B, CDK4I, INK4B, TP15, P15, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 1029; 1030
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Associations
    News
    Trials